04:53:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt bolag verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Portföljen inkluderar produkter som innehåller medicinsk cannabis (CBD), med störst inriktning mot kosttillskott och diverse behandlingsvård. Produkterna används exempelvis av patienter som lider av psoriasis, artros och håravfall. Störst verksamhet återfinns inom den nordiska marknaden, där produkterna vidaresäljs under eget varumärke.

Kalender

2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021
2022-04-11 09:28:54

CS MEDICA ("CS MEDICA" or the "Company") announces today that the Company has now finalised the Parts-per-billion (PBB) level THC test on their CANNASEN® CBD products,  showing no trace of THC. Hong Kong, Thailand, Malaysia, and Japan are the countries that have legalized CBD products and with the PPB THC test results, CS MEDICA is now able to sell CANNASEN® CBD products in those countries.

In preparation for targeting the Asian market, CS MEDICA has performed a "1/billion no trace of THC" (PPB) test of their CANNASEN®CBD products to comply with the regulations of Asia, which currently has legalized CBD products in Hong Kong, Thailand, Malaysia, and Japan. Where Europe requires a THC level below 0,02%(plant), the Dangerous Drugs Ordinance (DDO) of Asia requires a 0,00% level of THC currently messured by PPB test level 0,000000001(product).

The PPB THC analysis of the CANNASEN® CBD product line has been performed by the University of Naples Federico II, who certifies the PPB test by a quantitative analysis of cannabinoids and metabolites: CBDA, CBGA, CBG, CBD, D9-THC and acid D9-THC measured by ultra-high-performance liquid chromatography coupled with high-solution mass spectrometry (UHPLC Q-Orbitrap HRMS). The PPB test found no traceable THC or below 1 PPB THC in the following CANNASEN® CBD products:
  • Cannasen®CBD Arthritis Gel
  • Cannasen®CBD Psoriasis Gel
  • Cannasen®CBD Anti-Hair loss serum
  • Cannasen®CBD Pain Patch
  • Cannasen®CBD Protective Nasal Gel
  • Cannasen®CBD PSOR + ATOPIC Lotion
  • Cannasen®CBD Wound Gel

CS MEDICA now awaits the final approval from Hong Kong customs, before a test sale can be established in Hong Kong. Hence the company will extend the Asian area to also include the other countries, with cannabis products legalized (Thailand, Malaysia, and Japan).

With the PPB test successfully finalized CS MEDICA will be at the forefront of the very strict cannabis medical market of Asia, where illegal CBD products are currently being removed from the market, by Hong Kong customs.  Since mid-January, Hong Kong customs have initiated a special operation under the codename "Wind Rider", targeting cannabidiol (CBD) products containing tetrahydro-cannabinol (THC). The "Wind Rider" operation so far resulted in the seizing of about 25 000 items of CBD products from seven retail shops. The seized products containing THC included CBD oil, skincare products and pet treats with a total estimated market value of about $14,6 million.

With the successfully performed THC PPB test, CS MEDICA now complies with the very strict requirements of DDO and can sell the CANNASEN® CBD product line in Asia.